Conditions: Rheumatoid Arthritis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 15
Healthy volunteers: no

Brief summary:
The purpose of the study is to evaluate the effect of LX3305 on methotrexate (MTX) pharmacokinetics and to evaluate the safety and tolerability of LX3305 given over 14 days in subjects with stable rheumatoid arthritis that are receiving stable doses of MTX.

Detailed description:

Arms:
arm 1: Daily oral intake of LX3305 for 14 days. arm 2: Matching placebo dosing with daily oral intake for 14 days.

Interventions: intervention 1: LX3305 intervention 2: LX3305 Placebo intervention 3: Methotrexate
Intervention descriptions: intervention 1: Daily oral intake of LX3305 for 14 days. intervention 2: Matching placebo dosing with daily oral intake for 14 days. intervention 3: Once weekly stable-dose methotrexate.

Protocol document: